The DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.
MULTICENTER RANDOMIZED TRIAL COMPARING TACROLIMUS (FK506) AND CYCLOSPORINE IN THE PREVENTION OF RENAL ALLOGRAFT REJECTION1: A Report of the European Tacrolimus Multicenter Renal Study Group
Abstract
BACKGROUND: To confirm the results of a number of studies conducted in Europe, the United States, and Japan, this multicenter, randomized trial compared the 12-month efficacy and safety of tacrolimus- and cyclosporine-based immunosuppressive regimens in the prevention of renal allograft rejection. METHODS: A total of 448 renal transplant recipients were recruited from 15 centers and assigned to receive triple-drug therapy consisting of tacrolimus (n=303) or cyclosporine (n=145) in conjunction with azathioprine and low-dose corticosteroids. RESULTS: At 12 months after transplantation, tacrolimus therapy was associated with a significant reduction in the frequency of both acute (tacrolimus 25.9% vs. cyclosporine 45.7%; P<0.001 [absolute difference: 19.8%, 95% confidence interval: 10.0-29.6%]) and corticosteroid-resistant rejection (11.3% vs. 21.6%; P=0.001 [absolute difference: 10.3%, 95% confidence interval: 2.5-18.2%]). Actuarial 1-year patient (tacrolimus 93.0% vs. cyclosporine 96.5%; P=0.140) and graft survival rates (82.5% vs. 86.2%; P=0.380) did not differ significantly between the two treatment groups. Overall, the safety profiles of the tacrolimus- and cyclosporine-based regimens were quite comparable. Infections, renal impairment, neurological complications, and gastrointestinal complaints were frequently reported but were mostly reversible in both groups. Higher incidences of elevated serum creatinine, tremor, diarrhea, hyperglycemia, diabetes mellitus, and angina pectoris were reported in the tacrolimus treatment group, whereas acne, arrhythmia, gingival hyperplasia, and hirsutism were more frequent with cyclosporine treatment. CONCLUSIONS: The significant reduction in the incidence of episodes of allograft rejection observed with tacrolimus therapy may have important long-term implications given the prognostic influence of rejection on graft survival.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Solez, K., Axelsen, R. A., Benediktsson, H., Burdick, J. F., Cohen, A. H., Colvin, R. B., Croker, B. P., Droz, D., Dunnill, M. S., Halloran, P. F., et al. (1993) · Kidney International · doi:10.1038/ki.1993.259 · Cited by 1,424
SOLLINGER, H. W. (1995) · Transplantation · doi:10.1097/00007890-199508000-00003 · Cited by 1,363
(1996) · Transplantation · doi:10.1097/00007890-199604150-00008 · Cited by 1,055
Grinyo, J. M., GROTH, C. G., Pichlmayr, R., Sadek, S., Vanrenterghem, Y. F. C., Behrend, M., Luck, R. P., Moreso, F., Peeters, J. A. G., Rodicio, J. L., et al. (1995) · University of Groningen research database (University of Groningen / Centre for Information Technology) · Cited by 974
Self-citationEuropean Mycophenolate Mofetil Cooperative Study Group (1995) · The Lancet · doi:10.1016/s0140-6736(95)92534-1 · Cited by 927
A Comparison of Tacrolimus (FK 506) and Cyclosporine for Immunosuppression in Liver Transplantation
(1994) · New England Journal of Medicine · doi:10.1056/nejm199410273311702 · Cited by 920
ANTI-ESCHERICHIA COLI ALPHA-HAEMOLYSIN IN CONTROL AND PATIENT SERA
Emody, L., Batai, I., Kerényi, M., Székely, J., & Polyak, L. (1982) · The Lancet · doi:10.1016/s0140-6736(82)90183-0 · Cited by 800
LRISK FACTORS FOR CHRONIC REJECTION IN RENAL ALLOGRAFT RECIPIENTS
ALMOND, P. S., MATAS, A., GILLINGHAM, K., DUNN, D. L., PAYNE, W. D., NAJARIAN, J. S., PAUL, G., & RAINER, G. (1993) · Transplantation · doi:10.1097/00007890-199304000-00013 · Cited by 660
(1994) · The Lancet · doi:10.1016/s0140-6736(94)91766-3 · Cited by 656
A Randomized Clinical Trial of Cyclosporine in Cadaveric Renal Transplantation
The Canadian Multicentre Transplant Study Group (1983) · New England Journal of Medicine · doi:10.1056/nejm198310063091401 · Cited by 472
Cited by
Diabetes Mellitus after Kidney Transplantation in the United States
Kasiske, B. L., Snyder, J. J., Gilbertson, D., & Matas, A. J. (2003) · American Journal of Transplantation · doi:10.1034/j.1600-6143.2003.00010.x · Cited by 1,285
Kahan, B. D. (2000) · The Lancet · doi:10.1016/s0140-6736(00)02480-6 · Cited by 913
Clinical Pharmacokinetics and Pharmacodynamics of Tacrolimus in Solid Organ Transplantation
Staatz, C. E., & Tett, S. E. (2004) · Clinical Pharmacokinetics · doi:10.2165/00003088-200443100-00001 · Cited by 913
Groth, C. G., Bäckman, L., Morales, J.-M., Calne, R., Kreis, H., Lang, P., Touraine, J.-L., Claesson, K., Campistol, J. M., Durand, D., et al. (1999) · Transplantation · doi:10.1097/00007890-199904150-00017 · Cited by 878
Self-citationStrategies to Improve Long-Term Outcomes after Renal Transplantation
Pascual, M., Theruvath, T., Kawai, T., Tolkoff-Rubin, N., & Cosimi, A. B. (2002) · New England Journal of Medicine · doi:10.1056/nejmra011295 · Cited by 844
Metadata
- Authors
- Mayer, A. D., Dmitrewski, J., Squifflet, J.-P., Besse, T., Grabensee, B., Klein, B., Eigler, F. W., Heemann, U., Pichlmayr, R., Behrend, M., Vanrenterghem, Y., Donck, J., van Hooff, J., Christiaans, M., Morales, J. M., Andres, A., Johnson, R. W. G., Short, C., Buchholz, B., Rehmert, N., Land, W., Schleibner, S., Forsythe, J. L. R., Talbot, D., Neumayer, H.-H., Hauser, I., Ericzon, B.-G., Brattstr??m, C., Claesson, K., M??hlbacher, F., & Pohanka, E.
- Venue
- Transplantation
- Published
- 1997-08
- Volume
- 64
- Issue
- 3
- Pages
- 436-443
- ISSN
- 0041-1337 (ISSN-L)
- OpenAlex
- W2027371366
- Cited by
- 724
- References
- 17
- FWCI
- 34.69
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: MULTICENTER RANDOMIZED TRIAL COMPARING TACROLIMUS (FK506) AND CYCLOSPORINE IN THE PREVENTION OF RENAL ALLOGRAFT REJECTION1: A Report of the European Tacrolimus Multicenter Renal Study Group. https://app.cochat.ai/papers/10.1097/00007890-199708150-00012
- The paper
- Mayer, A. D., Dmitrewski, J., Squifflet, J.-P., Besse, T., Grabensee, B., Klein, B., Eigler, F. W., Heemann, U., Pichlmayr, R., Behrend, M., Vanrenterghem, Y., Donck, J., van Hooff, J., Christiaans, M., Morales, J. M., Andres, A., Johnson, R. W. G., Short, C., Buchholz, B., . . . Pohanka, E. (1997). MULTICENTER RANDOMIZED TRIAL COMPARING TACROLIMUS (FK506) AND CYCLOSPORINE IN THE PREVENTION OF RENAL ALLOGRAFT REJECTION1: A Report of the European Tacrolimus Multicenter Renal Study Group. Transplantation. https://doi.org/10.1097/00007890-199708150-00012
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.